ArriVent wows investors with promising China-developed lung cancer treatment
The drug startup’s shares rose 11% on their first trading day, after it raised $150 million in an upsized IPO underwritten by three major investment banks Key Takeaways: ArriVent raised…
Recent Articles
RELATED ARTICLES
-
Cancer drug maker Genfleet joins Hong Kong IPO influx
-
Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
1952.HK
-
A blockbuster cancer drug? TYK’s claims go under the microscope
2410.HK
-
NEWS WRAP: Hutchmed sells non-core asset to focus on cancer treatment
0013.HK HCM.US
- IPO-bound Dazhong Dental all smiles in market ripe for consolidation
